Enter a phrase above to search files and articles within the site.
Typically materials that are more than 5 years old will be archived
Displaying 1 - 10 of 10 results
Psoriatic Arthritis
https://www.niams.nih.gov/health-topics/psoriatic-arthritis
What is psoriatic arthritis? Psoriatic arthritis can occur in people who have psoriasis (scaly red and white skin patches). It affects the joints and areas where tissues attach to bone. The joints most often affected are: The outer joints of the fingers or toes. Wrists. Knees. Ankles. Lower back.
Osteonecrosis
https://www.niams.nih.gov/health-topics/osteonecrosis
What is osteonecrosis? Your bones are made up of living cells that need a blood supply to stay healthy. In osteonecrosis, blood flow to part of a bone is reduced. This causes death of bone tissue, and the bone can eventually break down and the joint will collapse. Osteonecrosis can happen to any bone, but most often it develops in the ends of long bones, such as the: Thigh bone. Upper arm bone. Less often, the bones of the elbows, ankles, feet, wrists, and hands are affected. When the disease involves part of a bone in a joint, it can
Rheumatoid Arthritis
https://www.niams.nih.gov/health-topics/rheumatoid-arthritis
What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic (long-lasting) disease that mostly affects joints, such as the wrist, hands, feet, spine, knees, and jaw. In joints, RA causes inflammation that leads to: Pain. Swelling Stiffness. Loss of function. Rheumatoid arthritis is an autoimmune disorder because the immune system attacks the healthy joint tissues. Normally, the immune system helps protect the body from infection and disease. RA may cause you to feel unusually tired, to have occasional fevers, and to have a loss of appetite. It also may cause other medical problems in the heart, lungs, blood, nerves, eyes
Stem Cell-Based Strategies Offer Personalized Approaches For Treating Inherited Skin Disease
https://www.niams.nih.gov/newsroom/spotlight-on-research/stem-cell-based-strategies-offer
Two new studies funded in part by NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) describe efforts to develop stem cell-based approaches for treating Epidermolysis Bullosa (EB), a rare, genetic skin disease. The findings, which were published jointly in the journal, Science Translational Medicine, may lead to individualized therapies for EB, and possibly other genetic diseases. People with EB have skin that is so fragile that the slightest friction causes blisters. The severity of the disease ranges from limited tearing of skin on the hands and feet to widespread blistering and scarring, including mucosal surfaces like the
Acne
https://www.niams.nih.gov/health-topics/acne
What is acne? Acne is a common skin condition that happens when hair follicles under the skin become clogged. Oil and dead skin cells plug the pores, and outbreaks of lesions (often called pimples or zits) can happen. Most often, the outbreaks occur on the face but can also appear on the back, chest, and shoulders. For most people, acne tends to go away by the time they reach their thirties, but some people in their forties and fifties continue to have this skin problem.
Epidermolysis Bullosa
https://www.niams.nih.gov/health-topics/epidermolysis-bullosa
What is epidermolysis bullosa? Epidermolysis bullosa is a group of rare diseases that cause fragile skin that leads to blisters and tearing. Tears, sores, and blisters in the skin happen when something rubs or bumps the skin. They can appear anywhere on the body. In severe cases, blisters may also develop inside the body. The symptoms of the disease usually begin at birth or during infancy and range from mild to severe.
Fibromyalgia
https://www.niams.nih.gov/health-topics/fibromyalgia
What is fibromyalgia? Fibromyalgia is a long-lasting or chronic disorder that causes muscle pain and fatigue (feeling tired). If you have fibromyalgia, you have pain and tenderness throughout your body. Sometimes you may have two or more chronic pain conditions at the same time, such as: Chronic fatigue syndrome. Endometriosis. Irritable bowel syndrome. Interstitial cystitis. Temporomandibular joint dysfunction (TMJ). Vulvodynia.
New rheumatoid arthritis drug targets NIH-discovered protein
https://www.niams.nih.gov/newsroom/press-releases/rheumatoid-arthritis-drug-targets-protein
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends
Accelerating Medicines Partnership (AMP)
https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines
The AMP RA/SLE Program brings together the NIH and medical community to address rheumatoid arthritis and lupus with diagnostic and drug advancements.